On Sex Differences in the Effects of Rapid-Acting Antidepressants
Patrick Robert Flaherty
Major depressive disorder (MDD) is an extremely debilitating sex-related disorder that currently affects over 300 million people worldwide. Women are more vulnerable to the precipitation of depressive symptoms and they are more likely to suffer from MDD as compared to men. Despite the pronounced sex differences in the manifestation of MDD and responsiveness of patients to drug treatment, clinical andpreclinical research on the neurobiological basis of this disorder and antidepressant drug development has focused on the male sex. Conventional antidepressant drug therapies are often ineffective and typically require weeks of chronic treatment to induce alleviation of depressive symptoms in MDD patients. Recently, the discovery of the rapid-acting antidepressant properties of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine revolutionized the field of antidepressant drug discovery. In the context of the current thesis we conducted a literature review on the current clinical and preclinical evidence highlighting the important role that sex may play in response to ketamine, as well as to other rapid-acting antidepressants.
Primary Advisor's Department
Stander Symposium project, College of Arts and Sciences
United Nations Sustainable Development Goals
Good Health and Well-Being; Quality Education
"On Sex Differences in the Effects of Rapid-Acting Antidepressants" (2021). Stander Symposium Projects. 2097.